Program
elinzanetant
Also written as “Elinzanetant (BAY3427080)”, “GSK1144814” and “BAY3427080”.
Its studies are mostly in Hot Flashes · Schizophrenia, led by 2 companies.
Drug pageElinzanetant: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 212 open or running | phase 3since Aug 26, 2021 | Aug 3, 2016 | Jan 22, 2027phase 1 · NCT07762287 |
| GlaxoSmithKlineits history only | 30 open or running | phase 1since Mar 4, 2010 | Mar 4, 2010 | none ahead |
Also a collaborator on its studies: Nerre Therapeutics and Quotient Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Mar 4, 2010.
- Dec 9, 2019Named elinzanetantINNProposed as its International Nonproprietary Name in WHO's List 122 · before, GSK1144814, BAY3427080
- Nov 25, 2020Phase 1 study in HealthyBayer · NCT04654897 · 6 enrolled · United Kingdom
- Apr 7, 2021Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT04845841 · 16 enrolled · Germany
- May 14, 20212 phase 1 studies in Multiple Endocrine Neoplasia Type 1Bayer · NCT04889287, NCT04903821
- Jul 5, 2021Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT04981431 · 62 enrolled · Japan
- Aug 26, 20212 phase 3 studies in Hot FlashesBayer · NCT05042362, NCT05030584
- Aug 26, 2021Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT05028608 · 16 enrolled · Germany
- Sep 20, 20212 phase 1 studies in Multiple Endocrine Neoplasia Type 1Bayer · NCT05061563, NCT05071729
- Oct 19, 2021Phase 3 study in Hot FlashesBayer · NCT05099159 · 400 enrolled · United States, Canada, Czechia and more
- Apr 25, 20222 phase 1 studies in Multiple Endocrine Neoplasia Type 1Bayer · NCT05351892, NCT05381142
- Jul 21, 20222 phase 1 studies in Multiple Endocrine Neoplasia Type 1Bayer · NCT05471817, NCT05481528
- Oct 17, 2022Phase 3 study in Hot FlashesBayer · NCT05587296 · 474 enrolled · Austria, Belgium, Canada and more
- Oct 27, 2023Phase 2 study in Sleep Disturbances Associated With MenopauseBayer · NCT06112756 · 110 enrolled · United States, Austria, Belgium and more
- Dec 21, 2023Phase 1 study in Multiple Endocrine Neoplasia Type 1Bayer · NCT06219902 · 64 enrolled · Canada
- Jul 15, 2026Phase 1 study in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in WomenBayer · NCT07762287 · 100 planned · Canada
Ahead
- Jan 22, 2027Primary completion: phase 1 study in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in WomenBayer · NCT07762287
TargetBeta
“An orally bioavailable neurokinin/tachykinin 1 receptor (NK1-receptor; NK1R; NK-1R) and NK3 receptor (NK-3R; NK3R) antagonist, that may be used to treat vasomotor symptoms in menopausal woman”NCIt, by rule
“Neurokinin 1 receptor antagonist; Neurokinin 3 receptor antagonist”ChEMBL 37, by rule
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07762287Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women · Canada | 1 | Recruiting | Bayer | Jan 22, 2027 | 100 |
| NCT06219902Multiple Endocrine Neoplasia Type 1 · Canada | 1 | Completed | Bayer | Apr 15, 2024 | 64 |
| NCT06112756Sleep Disturbances Associated With Menopause · United States, Austria, Belgium and more | 2 | Completed | Bayer | Aug 22, 2024 | 110 |
| NCT05587296Hot Flashes · Austria, Belgium, Canada and more | 3 | Active, not recruiting | Bayer | Jan 29, 2024 | 474 |
| NCT05481528Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Feb 7, 2023 | 51 |
| NCT05471817Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Sep 20, 2022 | 20 |
| NCT05381142Multiple Endocrine Neoplasia Type 1 · China | 1 | Completed | Bayer | Jul 11, 2022 | 16 |
| NCT05351892Multiple Endocrine Neoplasia Type 1 · United States | 1 | Completed | Bayer | Jun 9, 2022 | 18 |
| NCT05099159Hot Flashes · United States, Canada, Czechia and more | 3 | Completed | Bayer | Jun 13, 2023 | 400 |
| NCT05071729Multiple Endocrine Neoplasia Type 1 · United States | 1 | Completed | Bayer | Oct 19, 2022 | 31 |
| NCT05061563Multiple Endocrine Neoplasia Type 1 · Netherlands | 1 | Completed | Bayer | Dec 9, 2021 | 14 |
| NCT05030584Hot Flashes · United States, Belgium, Bulgaria and more | 3 | Completed | Bayer | Mar 29, 2023 | 628 |
| NCT05042362Hot Flashes · United States, Austria, Czechia and more | 3 | Completed | Bayer | Jul 25, 2023 | 396 |
| NCT05028608Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Oct 31, 2021 | 16 |
| NCT04981431Multiple Endocrine Neoplasia Type 1 · Japan | 1 | Completed | Bayer | Mar 13, 2022 | 62 |
| NCT04903821Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Mar 15, 2022 | 33 |
| NCT04889287Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Jul 23, 2021 | 16 |
| NCT04845841Multiple Endocrine Neoplasia Type 1 · Germany | 1 | Completed | Bayer | Jun 1, 2021 | 16 |
| NCT04654897Healthy · United Kingdom | 1 | Completed | Bayer | Oct 29, 2020 | 6 |
| NCT03596762Hot Flashes · United States, Canada, United Kingdom | 2 | Completed | Bayer | Nov 21, 2019 | 199 |
| NCT02865538Hot Flashes · United States | 2 | Completed | Bayer | Mar 28, 2017 | 76 |
| NCT01381419Schizophrenia · United Kingdom | 1 | Completed | GlaxoSmithKline | Apr 1, 2009 | 21 |
| NCT01209039Schizophrenia · United Kingdom | 1 | Completed | GlaxoSmithKline | Oct 25, 2009 | 41 |
| NCT01090440Schizophrenia · Australia | 1 | Completed | GlaxoSmithKline | Oct 9, 2009 | 16 |
How it is read
Names in the registry
- “Elinzanetant (BAY3427080)”, 15 entries
- “GSK1144814”, 7 entries
- “BAY3427080”, 2 entries
- “Elinzanetant (BAY 3427080) treatment A”, 1 entry
- “Elinzanetant (BAY 3427080) treatment B”, 1 entry
Conditions, from the studies’ own filings
- Hot Flashes, 13 studies
- Schizophrenia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.